Enhancement of tumor response by farnesyltransferase inhibitor in C3H/HeJ hepatocarcinoma

Ji Young Kim, Jinsil Seong, Sung Hee Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Farnesyltransferase inhibitor (FTI) acts on ras, which can ultimately enhance radiosensitivity. The objective of this study was to explore whether FTI could potentiate the antitumor efficacy of radiation in vivo, particularly in radio-resistant hepatocarcinomas (HCa-I) syngeneic to C3H/HeJ mice. The presence of ras mutations was examined by PCR and DNA sequencing. C3H/HeJ mice, bearing HCa-I, were treated with FTI, LB42907, and 25 Gy radiation. FTI was orally administered, 60 mg/kg, twice daily for 30 days. The expression of regulating molecules was analyzed by Western blotting for p53, p21 WAK1/CIP1 , and the Bcl-2 family, such as Bcl-2, Bax, and Bcl-X L/s . In HCa-I, no ras mutations were detected. Downregulation of ras by FTI was most prominent at 4 h after treatment. In a tumor growth delay assay, FTI increased the effect of the tumor's radioresponse, with an enhancement factor of 1.32. Combined irradiation and FTI increased radiation-induced apoptosis; the peak apoptotic index was 3.6% with irradiation alone and with the drug alone but 7.1% in the combined treatment group. The analysis of apoptosis-regulating molecules by Western blotting showed upregulation of p53 and p21 WAF1/CIP1 in the combined treatment group compared with those in either of the single treatment groups, but the Bcl-2 family remained unchanged. FTI, in combination with radiation therapy, may have potential benefits in cancer treatment even if there are no ras mutations. FTI could inhibit ras activity but may also affect any protein that requires farnesylation for its activity.

Original languageEnglish
Pages (from-to)95-102
Number of pages8
JournalAnnals of the New York Academy of Sciences
Volume1030
DOIs
Publication statusPublished - 2004 Jan 1

Fingerprint

Farnesyltranstransferase
Tumors
Neoplasms
Inbred C3H Mouse
Radiation
Mutation
Bearings (structural)
Western Blotting
Protein Prenylation
Irradiation
Apoptosis
Therapeutics
Enhancement
Radiation Dosage
Molecules
Oncology
Radiation Tolerance
Radiotherapy
Radio
DNA Sequence Analysis

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

@article{139f4f6456e642e08aba61886aa5b07c,
title = "Enhancement of tumor response by farnesyltransferase inhibitor in C3H/HeJ hepatocarcinoma",
abstract = "Farnesyltransferase inhibitor (FTI) acts on ras, which can ultimately enhance radiosensitivity. The objective of this study was to explore whether FTI could potentiate the antitumor efficacy of radiation in vivo, particularly in radio-resistant hepatocarcinomas (HCa-I) syngeneic to C3H/HeJ mice. The presence of ras mutations was examined by PCR and DNA sequencing. C3H/HeJ mice, bearing HCa-I, were treated with FTI, LB42907, and 25 Gy radiation. FTI was orally administered, 60 mg/kg, twice daily for 30 days. The expression of regulating molecules was analyzed by Western blotting for p53, p21 WAK1/CIP1 , and the Bcl-2 family, such as Bcl-2, Bax, and Bcl-X L/s . In HCa-I, no ras mutations were detected. Downregulation of ras by FTI was most prominent at 4 h after treatment. In a tumor growth delay assay, FTI increased the effect of the tumor's radioresponse, with an enhancement factor of 1.32. Combined irradiation and FTI increased radiation-induced apoptosis; the peak apoptotic index was 3.6{\%} with irradiation alone and with the drug alone but 7.1{\%} in the combined treatment group. The analysis of apoptosis-regulating molecules by Western blotting showed upregulation of p53 and p21 WAF1/CIP1 in the combined treatment group compared with those in either of the single treatment groups, but the Bcl-2 family remained unchanged. FTI, in combination with radiation therapy, may have potential benefits in cancer treatment even if there are no ras mutations. FTI could inhibit ras activity but may also affect any protein that requires farnesylation for its activity.",
author = "Kim, {Ji Young} and Jinsil Seong and Kim, {Sung Hee}",
year = "2004",
month = "1",
day = "1",
doi = "10.1196/annals.1329.012",
language = "English",
volume = "1030",
pages = "95--102",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

Enhancement of tumor response by farnesyltransferase inhibitor in C3H/HeJ hepatocarcinoma. / Kim, Ji Young; Seong, Jinsil; Kim, Sung Hee.

In: Annals of the New York Academy of Sciences, Vol. 1030, 01.01.2004, p. 95-102.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enhancement of tumor response by farnesyltransferase inhibitor in C3H/HeJ hepatocarcinoma

AU - Kim, Ji Young

AU - Seong, Jinsil

AU - Kim, Sung Hee

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Farnesyltransferase inhibitor (FTI) acts on ras, which can ultimately enhance radiosensitivity. The objective of this study was to explore whether FTI could potentiate the antitumor efficacy of radiation in vivo, particularly in radio-resistant hepatocarcinomas (HCa-I) syngeneic to C3H/HeJ mice. The presence of ras mutations was examined by PCR and DNA sequencing. C3H/HeJ mice, bearing HCa-I, were treated with FTI, LB42907, and 25 Gy radiation. FTI was orally administered, 60 mg/kg, twice daily for 30 days. The expression of regulating molecules was analyzed by Western blotting for p53, p21 WAK1/CIP1 , and the Bcl-2 family, such as Bcl-2, Bax, and Bcl-X L/s . In HCa-I, no ras mutations were detected. Downregulation of ras by FTI was most prominent at 4 h after treatment. In a tumor growth delay assay, FTI increased the effect of the tumor's radioresponse, with an enhancement factor of 1.32. Combined irradiation and FTI increased radiation-induced apoptosis; the peak apoptotic index was 3.6% with irradiation alone and with the drug alone but 7.1% in the combined treatment group. The analysis of apoptosis-regulating molecules by Western blotting showed upregulation of p53 and p21 WAF1/CIP1 in the combined treatment group compared with those in either of the single treatment groups, but the Bcl-2 family remained unchanged. FTI, in combination with radiation therapy, may have potential benefits in cancer treatment even if there are no ras mutations. FTI could inhibit ras activity but may also affect any protein that requires farnesylation for its activity.

AB - Farnesyltransferase inhibitor (FTI) acts on ras, which can ultimately enhance radiosensitivity. The objective of this study was to explore whether FTI could potentiate the antitumor efficacy of radiation in vivo, particularly in radio-resistant hepatocarcinomas (HCa-I) syngeneic to C3H/HeJ mice. The presence of ras mutations was examined by PCR and DNA sequencing. C3H/HeJ mice, bearing HCa-I, were treated with FTI, LB42907, and 25 Gy radiation. FTI was orally administered, 60 mg/kg, twice daily for 30 days. The expression of regulating molecules was analyzed by Western blotting for p53, p21 WAK1/CIP1 , and the Bcl-2 family, such as Bcl-2, Bax, and Bcl-X L/s . In HCa-I, no ras mutations were detected. Downregulation of ras by FTI was most prominent at 4 h after treatment. In a tumor growth delay assay, FTI increased the effect of the tumor's radioresponse, with an enhancement factor of 1.32. Combined irradiation and FTI increased radiation-induced apoptosis; the peak apoptotic index was 3.6% with irradiation alone and with the drug alone but 7.1% in the combined treatment group. The analysis of apoptosis-regulating molecules by Western blotting showed upregulation of p53 and p21 WAF1/CIP1 in the combined treatment group compared with those in either of the single treatment groups, but the Bcl-2 family remained unchanged. FTI, in combination with radiation therapy, may have potential benefits in cancer treatment even if there are no ras mutations. FTI could inhibit ras activity but may also affect any protein that requires farnesylation for its activity.

UR - http://www.scopus.com/inward/record.url?scp=15044358035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15044358035&partnerID=8YFLogxK

U2 - 10.1196/annals.1329.012

DO - 10.1196/annals.1329.012

M3 - Article

VL - 1030

SP - 95

EP - 102

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -